FDA accuses firm of selling unapproved drugs
This article was originally published in The Tan Sheet
Executive Summary
Under a consent decree with FDA, Risingsun Health and the Center for Complimentary and Alternative Health in Livingston, Mont., agree to hire an independent expert for pre-market review of product claims and to certify the claims are compliant. The decree, which also prohibits the firms from selling unapproved new drugs, was filed in the U.S. District Court for the District of Montana and resolves charges the firm sold ineffective products. Prior to signing the decree, Risingsun made and distributed unapproved new drugs, including Black Salve, Cancema and Can-Support, purported to treat cancer, asthma, anemia and epilepsy, FDA said Oct. 13
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.